Edition:
India

Akorn Inc (AKRX.O)

AKRX.O on Nasdaq

3.83USD
16 Sep 2019
Change (% chg)

-- (--)
Prev Close
$3.83
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,037,425
52-wk High
$13.81
52-wk Low
$2.34

Latest Key Developments (Source: Significant Developments)

Akorn Receives FDA Approval For Azelastine Hydrochloride Nasal Spray
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Akorn Inc ::AKORN RECEIVES FDA APPROVAL FOR AZELASTINE HYDROCHLORIDE NASAL SPRAY, 0.15%.RECEIVED NEW ABBREVIATED NEW DRUG APPLICATION APPROVAL FROM U.S. FDA FOR AZELASTINE HYDROCHLORIDE NASAL SPRAY, 0.15%.  Full Article

Akorn Provides Preliminary Second Quarter 2019 Results
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - Akorn Inc ::AKORN PROVIDES PRELIMINARY SECOND QUARTER 2019 RESULTS.Q2 GAAP LOSS PER SHARE $0.89.Q2 REVENUE $178.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $171.9 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.07 -- REFINITIV IBES DATA.Q2 ADJUSTED NON-GAAP LOSS PER SHARE $0.02.SEES FY REVENUE $690 MILLION TO $710 MILLION.AFFIRMING NET REVENUE AND ADJUSTED EBITDA GUIDANCE FOR FULL YEAR OF 2019.NET LOSS FOR YEAR IS EXPECTED TO BE IN RANGE OF $273 TO $258 MILLION.  Full Article

Akorn Receives FDA Warning Letter
Tuesday, 25 Jun 2019 

June 25 (Reuters) - Akorn Inc ::AKORN RECEIVES FDA WARNING LETTER.AKORN INC - COMPANY WILL RESPOND TO FDA LETTER WITHIN REQUIRED 15 WORKING DAYS FROM RECEIPT OF LETTER.AKORN INC - HAS FULL CONFIDENCE IN QUALITY OF PRODUCTS MANUFACTURED AT SOMERSET FACILITY AND EXPECTS TO CONTINUE PRODUCTION AT PLANT.AKORN-GOT WARNING LETTER FROM FDA RELATED TO INSPECTION OF ITS SOMERSET, NEW JERSEY MANUFACTURING FACILITY IN JULY AND AUGUST OF 2018.AKORN INC - RECEIVED WARNING LETTER FROM FDA RELATED TO INSPECTION OF ITS SOMERSET, NEW JERSEY MANUFACTURING FACILITY IN JULY AND AUGUST OF 2018.  Full Article

Akorn Reports Q1 GAAP Loss Per Share Of $0.65
Tuesday, 7 May 2019 

May 7 (Reuters) - Akorn Inc ::AKORN PROVIDES PRELIMINARY FIRST QUARTER 2019 RESULTS AND FULL YEAR GUIDANCE.Q1 GAAP LOSS PER SHARE $0.65.Q1 REVENUE $166 MILLION VERSUS REFINITIV IBES ESTIMATE OF $153.5 MILLION.Q1 ADJUSTED NON-GAAP LOSS PER SHARE $0.10 INCLUDING ITEMS.Q1 EARNINGS PER SHARE VIEW $-0.20 -- REFINITIV IBES DATA.SEES FY REVENUE $690 MILLION TO $710 MILLION.FY2019 REVENUE VIEW $633.5 MILLION -- REFINITIV IBES DATA.SEES 2019 CAPEX OF ABOUT $40 MILLION .SEES 2019 NET LOSS EXPECTED IN RANGE OF $166 MILLION TO $151 MILLION.FULL YEAR 2019 GUIDANCE ANTICIPATES CONTINUED SEQUENTIAL IMPROVEMENT THROUGHOUT YEAR.  Full Article

Akorn Posts Q1 Revenue of $166 Million
Tuesday, 7 May 2019 

May 7 (Reuters) - Akorn Inc ::AKORN PROVIDES PRELIMINARY FIRST QUARTER 2019 RESULTS AND FULL YEAR GUIDANCE.Q1 GAAP LOSS PER SHARE $0.65.Q1 REVENUE $166 MILLION VERSUS REFINITIV IBES ESTIMATE OF $153.5 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.20 -- REFINITIV IBES DATA.Q1 ADJUSTED NON-GAAP LOSS PER SHARE $0.10 INCLUDING ITEMS.SEES FY REVENUE $690 MILLION TO $710 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.20 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $633.5 MILLION -- REFINITIV IBES DATA.FULL YEAR 2019 GUIDANCE ANTICIPATES CONTINUED SEQUENTIAL IMPROVEMENT THROUGHOUT YEAR.SEES 2019 NET LOSS EXPECTED IN RANGE OF $166 MILLION TO $151 MILLION.SEES 2019 CAPEX OF ABOUT MILLION.  Full Article

Akorn Inc Says Entered Into An Amended And Restated Credit Agreement
Thursday, 18 Apr 2019 

April 17 (Reuters) - Akorn Inc ::AKORN INC - ENTERED INTO AN AMENDED AND RESTATED CREDIT AGREEMENT.AKORN INC - A&R CREDIT AGREEMENT PROVIDES FOR A REVOLVING LINE OF CREDIT OF UP TO $150 MILLION ON AN UNCOMMITTED BASIS.AKORN INC - A&R CREDIT AGREEMENT EXTENDING MATURITY DATE BY 90 DAYS TO JULY 16, 2019.  Full Article

Akorn CEO Raj Rai to leave after court ruling against co
Saturday, 8 Dec 2018 

Dec 7 (Reuters) - Akorn Inc ::SUPREME COURT OF THE STATE OF DELAWARE RULES AGAINST AKORN, NEW CEO SEARCH UNDERWAY.AKORN INC - CURRENT CEO RAJ RAI HAS DECIDED TO RETIRE.AKORN - AKORN'S BOARD ANNOUNCED THAT IT IS ENGAGED IN A FORMAL SEARCH FOR A NEW CHIEF EXECUTIVE OFFICER TO LEAD COMPANY INTO ITS NEXT PHASE.AKORN INC - CEO RAJ RAI WILL ASSIST BOARD TO ENSURE A SMOOTH TRANSITION AND REMAIN IN HIS ROLE UNTIL HIRING DATE OF NEW CHIEF EXECUTIVE.AKORN INC - HAS RECEIVED SEVERAL NEW ABBREVIATED NEW DRUG APPLICATION APPROVALS FROM FOOD AND DRUG ADMINISTRATION.  Full Article

Akorn Receives Product Approval
Tuesday, 27 Nov 2018 

Nov 26 (Reuters) - Akorn Inc ::AKORN RECEIVES PRODUCT APPROVAL.AKORN - RECEIVED NEW ANDA APPROVAL FROM U.S. FDA FOR DICLOFENAC SODIUM TOPICAL GEL, 1%.  Full Article

Paulson Ups Stake In NXP Semiconductor; Cuts In Altice USA
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - PAULSON & CO INC ::PAULSON & CO INC CUTS SHARE STAKE IN ALTABA INC BY 5.5 PERCENT TO 1.73 MILLION SHARES - SEC FILING.PAULSON & CO INC UPS SHARE STAKE IN NXP SEMICONDUCTOR NV BY 27.9 PERCENT TO 2.6 MILLION SHARES.PAULSON & CO INC CUTS SHARE STAKE IN ALTICE USA BY 85.2 PERCENT TO 25,685 CLASS A SHARES.PAULSON & CO INC CUTS SHARE STAKE IN HORIZON PHARMA BY 6.5 PERCENT TO 7.2 MILLION SHARES.PAULSON & CO INC CUTS SHARE STAKE IN AKORN INC BY 70.5 PERCENT TO 520,000 SHARES.  Full Article

Fresenius Costs Related To Akorn Total 60 Mln Euros So Far - CEO
Friday, 18 May 2018 

May 18 (Reuters) - Fresenius CEO at Annual General Meeting::CEO SAYS COSTS RELATED TO AKORN <<>> TRANSACTION TOTAL 60 MILLION EUROS SO FAR.SAYS MUST EXAMINE WHETHER PROVISIONS NEED TO BE SET ASIDE IN CONNECTION WITH AKORN.FRESENIUS CEO SAYS HAVE FILED FOR SUFFICIENT LEVEL OF DAMAGES FROM AKORN.  Full Article

Why would allegedly defrauded Akorn investors want … more Akorn stock?

The generic drugmaker Akorn is facing a world of trouble. The German healthcare giant Fresenius, which received court approval last year to walk away from a $4.75 billion deal to acquire Akorn, is suing Akorn in Delaware Chancery Court for damages from the busted deal. The U.S. Food and Drug Administration is investigating data integrity issues at the company’s manufacturing plants, issuing two warning letters this year about potential regulatory shortcomings. Akorn is also feeling p